Breast cancer drug study looks at body fat changes
NCT ID NCT03697577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how three common breast cancer drugs (abemaciclib, ribociclib, or palbociclib) change body fat and muscle in 30 people with ER+/HER2- breast cancer that has spread. Participants get CT and DEXA scans before and after 24 weeks of treatment. The goal is to understand side effects on body composition, not to test if the drugs work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center
The Bronx, New York, 10461, United States